Monday - May 5, 2025
CORAL GABLES, Fla., March 20, 2023 (GLOBE NEWSWIRE) -- MSP Recovery, Inc. d/b/a LifeWallet (NASDAQ: LIFW) (“LifeWallet”, or “LIFW” or “the Company”), a Medicare, Medicaid, commercial, and secondary payer reimbursement recovery and technology leader, today announced that the Company will release its fourth quarter and full year 2022 financial results after the market closes on Friday, March 31, 2023.
LifeWallet will host a conference call and live webcast to review the Company’s fourth quarter and full year results for investors and analysts at 4:30 p.m. Eastern Time on Friday, March 31, 2023. To access this call, we encourage you to pre-register using this link: LifeWallet Q4 2022 Earnings Pre Registration.
A live webcast of the conference call will be accessible from the Investors section of LifeWallet’s website at https://www.lifewallet.com.
A replay of the webcast will be archived and accessible at investor.lifewallet.com.
About LifeWallet
Founded in 2014 as MSP Recovery, LifeWallet has become a Medicare, Medicaid, commercial, and secondary payer reimbursement recovery leader, disrupting the antiquated healthcare reimbursement system with data-driven solutions to secure recoveries from responsible parties. LifeWallet provides comprehensive solutions for multiple industries including healthcare, legal, education, and sports NIL, while innovating technologies to help save lives. For more information, visit: lifewallet.com.
For Investors:
ICR, Inc.
Marc Griffin
Marc.Griffin@icrinc.com
For Media:
ICR, Inc.
lifewallet@icrinc.com
Last Trade: | US$1.96 |
Daily Change: | 0.04 1.87 |
Daily Volume: | 3,479 |
Market Cap: | US$144.430M |
November 14, 2024 November 14, 2023 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load